BCMLT
NTLA icon

Beacon Capital Management LLC (Tennessee)’s Intellia Therapeutics NTLA Stock Holding History

Beacon Capital Management LLC (Tennessee)’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-164
Closed -$1.17K – 1145
2025
Q1 		$1.17K Buy
+164
New +$1.66K ﹤0.01% 1022

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Beacon Capital Management LLC (Tennessee)'s NTLA Position: Q2 2025 in Review

Beacon Capital Management LLC (Tennessee) sold out of Intellia Therapeutics (NTLA) in Q2 2025, closing a stake of 164 shares — an estimated $1.17K sold.

Beacon Capital Management LLC (Tennessee) first reported a position in NTLA in Q1 2025 and held it in 1 quarter. The position peaked at $1.17K in Q1 2025. 281 funds tracked by Wall St. Rank hold NTLA as of Q2 2025.

  • Beacon Capital Management LLC (Tennessee) reported no remaining Intellia Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Beacon Capital Management LLC (Tennessee) sold 164 Intellia Therapeutics shares in Q2 2025, an estimated $1.17K.
  • Beacon Capital Management LLC (Tennessee) first reported a position in Intellia Therapeutics in Q1 2025 and held it in 1 quarter.
  • Beacon Capital Management LLC (Tennessee)'s Intellia Therapeutics position peaked at $1.17K in Q1 2025.
  • 281 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2025.

Based on Beacon Capital Management LLC (Tennessee)'s 13F filing for Q2 2025, filed 17 Jul 2025.